Objective To evaluate the safety and effectiveness of the domestic SR-ENS-600 single-port robotic laparoscopic system for benign gynecological diseases. Methods This study was conducted as a single-arm design. A total of 28 patients who underwent surgery at the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital between Jan. 2023 and Apr. 2025 were enrolled. The procedures were performed using the domestic SR-ENS-600 single-port robotic laparoscopic system. Among them, 14 patients underwent single-port robotic ovarian cystectomy/adnexectomy (SRC group), 2 underwent single-port robotic myomectomy (SRM group), and 12 underwent single-port robotic total hysterectomy (SRH group). The surgical success rate, operative time, blood loss, time to return of bowel activity, postoperative hospital stay, complications, and adverse events were recorded. Results The surgical success rate was 100.0%, with no conversions to laparotomy or multi-port laparoscopic surgery. The operative time was (90.50±34.20) min in the SRC group, 65.00 min and 152.00 min for the 2 cases in the SRM group, (165.33±40.22) min in the SRH group, and (123.86±52.17) min for all the patients. The blood loss was 5.00 (5.00, 6.25) mL in the SRC group, 5.00 mL and 50.00 mL for the 2 cases in the SRM group, 20.00 (10.00, 50.00) mL in the SRH group, and 10.00 (5.00, 27.50) mL for all the patients. The time to return of bowel activity was (16.71±6.47) h in the SRC group, 17.00 h and 20.00 h for the 2 cases in the SRM group, (25.21±7.46) h in the SRH group, and (20.48±7.79) h for all patients. The postoperative hospital stay was 2.00 (2.00, 3.00) d in the SRC group, 2.00 d for both cases in the SRM group, 5.00 (2.25, 5.75) d in the SRH group, and 3.00 (2.00, 3.75) d for all the patients. No intraoperative or postoperative complications, reoperations, or serious adverse events occurred in any patients. Conclusion Preliminary results indicate that the domestic SR-ENS-600 single-port robotic laparoscopic system is safe and effective for the treatment of benign gynecological diseases, with less blood loss and shorter postoperative hospital stay.